Baseline demographics. Results are given as No (%) unless otherwise staed
| 0–6 Months | 0–12 Months | 0–24 Months | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| LEF1-150 (n=133) | PL (n=92) | SSZ1-150 (n=133) | LEF (n=80) | SSZ (n=76) | PL-SSZ (n=41) | LEF (n=60) | SSZ (n=60) | PL-SSZ (n=26) | |||
| Female | 101 (76) | 69 (75) | 92 (69) | 60 (75) | 50 (66) | 31 (76) | 49 (82) | 41 (68) | 19 (73) | ||
| Mean age (years) | 58 (11) | 59 (12) | 59 (11) | 58 (11) | 59 (11) | 59 (12) | 58 (11) | 59 (11) | 59 (12) | ||
| Mean (SD) disease duration (years) | 8 (9) | 6 (7) | 7 (10) | 6 (7) | 7 (9) | 6 (7) | 7 (8) | 6 (9) | 5 (5) | ||
| ⩽2 | 50 (38) | 41 (45) | 56 (42) | 33 (41) | 32 (42) | 19 (46) | 25 (42) | 26 (43) | 12 (46) | ||
| >2 | 83 (62) | 51 (55) | 77 (58) | 47 (59) | 44 (58) | 22 (54) | 35 (58) | 34 (57) | 26 (54) | ||
| Functional class | |||||||||||
| I | 10 (8) | 3 (3) | 6 (5) | 5 (6) | 3 (4) | 1 (2) | 3 (5) | 1 (2) | 0 (0) | ||
| II | 74 (56) | 50 (54) | 76 (57) | 46 (58) | 45 (59) | 21 (51) | 36 (60) | 38 (63) | 15 (58) | ||
| III | 49 (37) | 39 (42) | 51 (38) | 28 (36) | 28 (37) | 19 (46) | 21 (35) | 21 (35) | 11 (42) | ||
| No prior DMARDs1-150 | 53 (40) | 49 (53) | 68 (51) | 31 (39) | 39 (51) | 21 (51) | 24 (40) | 32 (53) | 13 (50) | ||
| NSAID1-150 use | 112 (84) | 78 (85) | 99 (74) | 66 (83) | 55 (72) | 33 (81) | 48 (80) | 47 (78) | 22 (85) | ||
| Steroid use | 45 (34) | 30 (33) | 42 (32) | 35 (44) | 36 (47) | 19 (46) | 30 (50) | 31 (52) | 12 (46) | ||
↵1-150 DMARDs = disease modifying antirheumatic drugs; NSAID = non-steroidal antirheumatic drug; LEF = leflunomide; PL = placebo; SSZ = sulfasalazine.